Spain sees faster scleroderma diagnosis and emerging therapies

The systemic autoimmune disease scleroderma affects about 13,000 people in Spain and carries the highest mortality among systemic autoimmune disorders. Rheumatologist Dr. Patricia Carreira of Hospital Universitario 12 de Octubre highlighted the importance of early detection, noting that symptoms such as Raynaud’s phenomenon, hand swelling and digestive problems can prompt quicker diagnosis.

In 2026, diagnosis times have shortened, allowing patients to begin treatment sooner. International collaboration through the EUSTAR registry, which contains data on over 25,000 patients, has deepened understanding of severe complications like interstitial lung disease and pulmonary hypertension. Recent clinical trials have produced therapies that slow disease progression, and several promising drugs are awaiting approval. Innovative approaches under investigation include cellular treatments such as CAR‑T cells and bispecific antibodies, as well as personalized medicine that integrates clinical, genetic and molecular data.

Patient advocate Beatriz García, president of the Spanish Scleroderma Association, called for improved early‑diagnosis pathways, equitable access to multidisciplinary care across the country, expanded research funding, greater public awareness, and stronger psychological and social support for patients and families.